Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Argatroban is a synthetic direct thrombin inhibitor with anticoagulant and antiplatelet activity used for the prevention and treatment of heparin-related thrombosis. Intravenous administration.
At the time of the last update, we found no published data on its excretion in breast milk.
Being a tripeptide or peptidomimetic compound derived from L-Arginine, it has zero oral bioavailability due to poor enteral absorption, since, due to its protein nature, it is degraded in the gastrointestinal tract, not being absorbed and to presystemic hepatic extraction (Hauptmann 2002), which hinders its passage to infant plasma from ingested breast milk.
Its short half-life allows minimizing risks, waiting 3-4 hours until breastfeeding is resumed.